首页> 外文期刊>Microbial Pathogenesis >Novel metabolites from Trichoderma atroviride against human prostate cancer cells and their inhibitory effect on Helicobacter pylori and Shigella toxin producing Escherichia coli
【24h】

Novel metabolites from Trichoderma atroviride against human prostate cancer cells and their inhibitory effect on Helicobacter pylori and Shigella toxin producing Escherichia coli

机译:来自Trichoderma阿托韦的新代谢物对抗人前列腺癌细胞及其对幽门螺杆菌和志贺氏菌毒素产生大肠杆菌的抑制作用

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The present study aimed to purify and identify the metabolites from T. atroviride using high-performance liquid chromatography (HPLC) and H-1 and C-13 nuclear magnetic resonance spectrometer (NMR) followed by analyzing their toxicological, antibacterial and anticancer properties. This work identified two metabolites - TM1 and TM2. TM1 was in two forms: (i) 1, 3-dione-5, 5-dimethylcyclohexane; and, (ii) 2-enone-3hydroxy - 5,5-dimethylcylohex, while TM2 was 4H-1,3-dioxin-4-one-2,3,6-trimethyl. These metabolites did not exhibit any irritant or allergic reaction as revealed by HET- CAM test. TM2 significantly inhibited the growth of H. pylori and Shigella toxin producing Escherichia coli (STEC) as evident by in vitro and microscopic observations of bacterial cell death. TM2 also induced the cell death and cytotoxicity, as revealed by cell viability test and western blot analysis. According to microscopic, flow cytometer and western blot analysis, TM2 treated cells displayed higher ROS, cell death, and apoptosis-related protein expression than TM1 and control. This study concluded that TM2 derived from T. atroviride was a potential therapeutic agent for anti-prostate cancer and antibiotic agent against MDR- H. pylori and STEC and it is also recommended to carry out further in vivo animal model experiments with improved stability of the metabolites for future pharmaceutical trails.
机译:本研究旨在使用高效液相色谱(HPLC)和H-1和C-13核磁共振光谱仪(NMR)纯化和鉴定来自T.Atroviridide的代谢物。随后通过分析其毒理学,抗菌和抗癌性能。这项工作确定了两种代谢物 - TM1和TM2。 TM1有两种形式:(i)1,3-二酮-5,5-二甲基环己烷;并且(ii)2-烯酮-3羟基 - 5,5-二甲基硅胶,而TM2为4H-1,3-二恶蛋白-4-一度-2,3,6-三甲基。这些代谢物未表现出任何刺激性或过敏反应,如HET-CAM试验所揭示的。 TM2显着抑制H. Pylori和Shigella Toxin的生长,通过体外和微观观察细菌细胞死亡的显明性产生了大肠杆菌(StEC)。 TM2还诱导细胞死亡和细胞毒性,如细胞活力测试和蛋白质印迹分析所揭示。根据显微镜,流式细胞仪和蛋白质印迹分析,TM2处理的细胞显示ROS,细胞死亡和凋亡相关蛋白表达,而不是TM1和控制。该研究得出结论,衍生自T.Atroviride的TM2是针对MDR- H.幽门螺杆菌和STEC的抗前列腺癌和抗生素剂的潜在治疗剂,并且还建议在体内动物模型实验中进一步进行,具有改善的稳定性未来制药小径的代谢物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号